This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
The facility will manufacture tablets, capsules, and injections for the oncology segment
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Hepatitis B infects over 40 million people in India
Dr Madhu will oversee Apollo's hospital business and will focus on continuing to deliver the world's best clinical outcomes
Lonza plans to invest approximately CHF 500 million to upgrade the facility
A five-day inspection was concluded successfully with no critical and no major observations raised
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
More than 10,000 scientific publications containing EUDRAGIT
Subscribe To Our Newsletter & Stay Updated
